share_log

TransCode Therapeutics Reports Initial Dosing In Fourth Cohort Of Phase 1 Clinical Trial With TTX-MC138

Benzinga ·  Mar 27 20:42
  • First patient in Cohort four has been treated with TTX-MC138
  • Ten patients have been treated with TTX-MC138 at escalating dose levels
  • Additional patients being evaluated for eligibility for expanded enrollment
    • No significant safety or dose limiting toxicities have been reported
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 1790

Recommended

Write a comment